Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3154
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Antonio, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 289–300 of 3,154 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 2Phase 3 Interventional

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

NCT04559139
View directory record Official record
Conditions
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy, Partial Hepatectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
367
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Rusfertide, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
80
States / cities
Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT06244771
View directory record Official record
Conditions
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
Interventions
FMC-376
Drug
Lead sponsor
Frontier Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Active, not recruiting Phase 2 Interventional

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

NCT07767474
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ATX-898, ATX-898, fulvestrant, ribociclib
Drug
Lead sponsor
Antares Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Fort Worth, Texas • Houston, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Recruiting Not applicable Interventional

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

NCT05745285
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Interventions
LLS Program
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Miami, Florida • Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 6, 2026, 5:45 AM EST